Chimerix Inc.

2.06+0.2400+13.19%Vol 24.35M1Y Perf -76.55%
Jun 24th, 2022 16:00 DELAYED
BID2.03 ASK2.07
Open1.86 Previous Close1.82
Pre-Market- After-Market2.01
 - -  -0.05 -2.43%
Target Price
8.75 
Analyst Rating
Strong Buy 1.00
Potential %
324.76 
Finscreener Ranking
★★★+     52.02
Insiders Trans % 3/6/12 mo.
100/67/56 
Value Ranking
★+     44.08
Insiders Value % 3/6/12 mo.
100/70/59 
Growth Ranking
★★     44.69
Insiders Shares Cnt. % 3/6/12 mo.
100/89/79 
Income Ranking
 —    -
Price Range Ratio 52W %
10.52 
Earnings Rating
Strong Sell
Market Cap180.12M 
Earnings Date
4th Aug 2022
Alpha-0.00 Standard Deviation0.23
Beta1.33 

Today's Price Range

1.792.47

52W Range

1.278.78

5 Year PE Ratio Range

-6.60-2.80

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
32.90%
1 Month
15.08%
3 Months
-58.47%
6 Months
-71.31%
1 Year
-76.55%
3 Years
-38.69%
5 Years
-61.85%
10 Years
-

TickerPriceChg.Chg.%
CMRX2.060.240013.19
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
3.50
4.10
0.05
0.05
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
79.60
-18 017.50
-17 996.10
-18 023.40
-
RevenueValueIndustryS&P 500US Markets
559.00K
0.01
-48.37
-18.68
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.35-0.2820.00
Q04 2021-0.11-0.45-309.09
Q03 2021-0.21-0.210.00
Q02 2021-0.19-0.21-10.53
Q01 2021-0.48-0.1862.50
Q04 2020-0.20-0.195.00
Q03 2020-0.17-0.18-5.88
Q02 2020-0.18-0.1611.11
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.24-155.81Negative
9/2022 QR2.302.02KPositive
12/2022 FY1.581.54KPositive
12/2023 FY-0.89-1 383.33Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.24
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume24.35M
Shares Outstanding87.44K
Shares Float83.50M
Trades Count62.44K
Dollar Volume53.02M
Avg. Volume3.91M
Avg. Weekly Volume4.52M
Avg. Monthly Volume3.68M
Avg. Quarterly Volume3.53M

Chimerix Inc. (NASDAQ: CMRX) stock closed at 2.06 per share at the end of the most recent trading day (a 13.19% change compared to the prior day closing price) with a volume of 24.35M shares and market capitalization of 180.12M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Chimerix Inc. CEO is Michael Sherman.

The one-year performance of Chimerix Inc. stock is -76.55%, while year-to-date (YTD) performance is -67.96%. CMRX stock has a five-year performance of -61.85%. Its 52-week range is between 1.27 and 8.78, which gives CMRX stock a 52-week price range ratio of 10.52%

Chimerix Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 2.93, a price-to-sale (PS) ratio of 225.24, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -93.43%, a ROC of -108.03% and a ROE of -115.62%. The company’s profit margin is -%, its EBITDA margin is -17 996.10%, and its revenue ttm is $559.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Chimerix Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. Chimerix Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Chimerix Inc. is Strong Buy (1), with a target price of $8.75, which is +324.76% compared to the current price. The earnings rating for Chimerix Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Chimerix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Chimerix Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.61, ATR14 : 0.26, CCI20 : 156.28, Chaikin Money Flow : 0.01, MACD : -0.33, Money Flow Index : 75.44, ROC : 10.16, RSI : 49.41, STOCH (14,3) : 65.83, STOCH RSI : 1.00, UO : 49.51, Williams %R : -34.17), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Chimerix Inc. in the last 12-months were: David Jakeman (Sold 7 890 shares of value $46 767 ), Fred A. Middleton (Buy at a value of $95 157), Martha J. Demski (Buy at a value of $16 100), Michael T. Andriole (Buy at a value of $25 635), Robert J. Meyer (Buy at a value of $23 470)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Chimerix Inc.

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes a treatment for acute myeloid leukemia (or AML) and an antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment--pharmaceuticals.

CEO: Michael Sherman

Telephone: +1 919 806-1074

Address: 2505 Meridian Parkway, Durham 27713, NC, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

56%44%

Bearish Bullish

53%47%

News

Stocktwits